Bank of New York Mellon Corp lowered its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 1.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,625 shares of the biopharmaceutical company’s stock after selling 1,373 shares during the period. Bank of New York Mellon Corp owned approximately 0.22% of ChemoCentryx worth $784,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of the stock. American Century Companies Inc. purchased a new stake in ChemoCentryx during the first quarter worth approximately $297,000. Teachers Advisors LLC increased its position in shares of ChemoCentryx by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 40,288 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 3,114 shares during the last quarter. Strs Ohio increased its position in shares of ChemoCentryx by 19.0% in the first quarter. Strs Ohio now owns 52,600 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 8,400 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of ChemoCentryx during the fourth quarter worth about $483,000. Finally, Adams Diversified Equity Fund Inc. increased its position in shares of ChemoCentryx by 2.8% in the first quarter. Adams Diversified Equity Fund Inc. now owns 87,900 shares of the biopharmaceutical company’s stock worth $640,000 after buying an additional 2,400 shares during the last quarter. Institutional investors own 49.37% of the company’s stock.
Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) opened at 6.87 on Friday. ChemoCentryx, Inc. has a 52-week low of $4.06 and a 52-week high of $10.80. The stock’s market capitalization is $334.61 million. The stock has a 50 day moving average of $9.33 and a 200-day moving average of $7.71.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/bank-of-new-york-mellon-corp-decreases-position-in-chemocentryx-inc-ccxi-updated-updated.html.
A number of research analysts have issued reports on CCXI shares. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, July 17th. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Finally, BidaskClub downgraded shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th.
In other news, insider Petrus Bekker sold 65,509 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $9.17, for a total transaction of $600,717.53. Following the completion of the transaction, the insider now directly owns 89,839 shares of the company’s stock, valued at approximately $823,823.63. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold 223,649 shares of company stock valued at $2,157,360 over the last three months. 26.80% of the stock is currently owned by corporate insiders.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
What are top analysts saying about ChemoCentryx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ChemoCentryx Inc. and related companies.